Quick Answer
Inhibikase Therapeutics, Inc. reported Research And Development Expense of $29.79 million for the year ending 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +73.1% in Research And Development Expense from 2024 to 2025.
- This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $283.1 thousand | Q2 2020: $263.2 thousand | Q3 2020: $120.6 thousand | Q1 2021: $2.43 million | Q2 2021: $2.38 million | Q3 2021: $3.15 million | Q1 2022: $3.02 million | Q2 2022: $2.98 million | Q3 2022: $2.98 million | Q1 2023: $2.85 million | Q2 2023: $4.54 million | Q3 2023: $3.23 million | Q1 2024: $2.75 million | Q2 2024: $3.08 million | Q3 2024: $4.19 million | Q1 2025: $10.51 million | Q2 2025: $5.27 million | Q3 2025: $7.65 million.
- Over the full 6 years of available data (2020 to 2025), Inhibikase Therapeutics, Inc.'s Research And Development Expense has grown by 3,233.3%.
- Historical annual values: Fiscal year 2025: $29.79 million | Fiscal year 2024: $17.21 million | Fiscal year 2023: $13.62 million | Fiscal year 2022: $12.03 million | Fiscal year 2021: $11.36 million | Fiscal year 2020: $893.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: